Improving Engraftment, Islet Survival and Metabolic Reserve in Clinical Islet Transplantation Using Caspase Inhibitor - IDN-6556

Trial Profile

Improving Engraftment, Islet Survival and Metabolic Reserve in Clinical Islet Transplantation Using Caspase Inhibitor - IDN-6556

Completed
Phase of Trial: Phase I/II

Latest Information Update: 11 Jul 2016

At a glance

  • Drugs Emricasan (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 05 Jul 2016 Status changed from active, no longer recruiting to completed.
    • 01 Dec 2015 Planned End Date changed from 1 Jun 2015 to 1 Mar 2017 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top